Liquid Alpha1-Proteinase Inhibitor (Human)

BIOLOGICAL2 trials

Sponsors

Grifols Therapeutics LLC

Conditions

Alpha1-Antitrypsin DeficiencyCOVID-19

Phase 1

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin Deficiency

CompletedNCT04722887

Grifols Therapeutics LLCAlpha1-Antitrypsin Deficiency

Start: 2021-08-13End: 2025-08-01Updated: 2025-12-12

Phase 2

Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) in Hospitalized Participants With Coronavirus Disease (COVID-19)

TerminatedNCT04547140

Grifols Therapeutics LLCCOVID-19

Start: 2021-01-29End: 2022-01-28Updated: 2023-03-22

Related Papers

α1-Antitrypsin deficiency and the risk of COVID-19: an urgent call to action

The Lancet Respiratory Medicine2021-01-2156 citations